Biovance Capital Partners
Overview
Biovance Capital Partners is a venture capital firm that invests in early-stage biopharma companies developing new therapeutics across Europe, with a focus on Portugal, Spain, and Italy.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Mondego Bio | Sep 2025 | Series A | Lead |
| Laigo Bio | Mar 2026 | Seed | Lead |
| Vaxdyn | Sep 2026 | Series A | Lead |
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Biovance Capital Partners based?
Biovance Capital Partners is headquartered in Lisbon, Portugal.
When was Biovance Capital Partners founded?
Biovance Capital Partners was founded in 2024.
How many portfolio companies does Biovance Capital Partners have?
Biovance Capital Partners has 3 portfolio companies in Caplight's dataset.
What are some companies in Biovance Capital Partners's portfolio?
Portfolio companies visible on Caplight include Mondego Bio, Laigo Bio, Vaxdyn.
What was Biovance Capital Partners's most recent investment shown here?
Biovance Capital Partners's most recent investment in this portfolio sample was in Vaxdyn in 2026.
What sectors does Biovance Capital Partners focus on?
Biovance Capital Partners focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences.
What company stages does Biovance Capital Partners focus on?
Biovance Capital Partners typically invests at the Early stage.
What is Biovance Capital Partners's AUM?
Biovance Capital Partners's assets under management are estimated between $61.6M and $64.8M.